FDA Prescribing Information Comparison
Wegovy vs Zepbound vs Wegovy Tablets vs Foundayo vs Saxenda: FDA Label Comparison
Side-by-side comparison of all 5 FDA-approved GLP-1 medications based on official FDA prescribing information. All facts are quoted directly from DailyMed and manufacturer Prescribing Information archives.
Key takeaways (FDA label facts)
- •All 5 medications are FDA-approved to reduce excess body weight and maintain weight reduction long term: Used in combination with a reduced-calorie diet and increased physical activity in adults with obesity or overweight accompanied by weight-related comorbidities. Certain medications have additional labeled indications, such as cardiovascular risk reduction and MASH for Wegovy, and moderate to severe obstructive sleep apnea (OSA) for Zepbound.
- •Administration routes differ: 3 medications (Wegovy, Zepbound, and Saxenda) are administered by subcutaneous injection, while 2 (Wegovy Tablets and Foundayo) are taken as oral daily tablets.
- •Dosing frequencies differ: Wegovy and Zepbound are administered once weekly, whereas Wegovy Tablets, Foundayo, and Saxenda are administered once daily.
| Medication & Molecule | Dosage Form & Route | Dosing Frequency | FDA-Approved Indications (Label Quotes) | Prescribing Info |
|---|---|---|---|---|
| Wegovy (semaglutide) Weekly Pen | WEGOVY (semaglutide) injection, for subcutaneous use | Administer WEGOVY injection once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals. | FDA label says "WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. ( 1 ) • to reduce excess body weight and maintain weight reduction long term in: o adults and pediatric patients aged 12 years and older with obesity. ( 1 ) o adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) • for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults." | DailyMed / USPL Reviewed: 2026-11-04 |
| Zepbound (tirzepatide) Weekly Pen | ZEPBOUND ® (tirzepatide) Injection, for subcutaneous use | The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks. Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved. | FDA label says "ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity." | DailyMed / USPL Reviewed: 2026-11-04 |
| Wegovy Tablets (oral semaglutide) Oral Pill | WEGOVY (semaglutide) tablets, for oral use | Take WEGOVY tablets orally once-daily on an empty stomach in the morning with water (up to 4 ounces). Do not take with other liquids besides water. | FDA label says "WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. ( 1 ) • to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition." | DailyMed / USPL Reviewed: 2026-11-06 |
| Foundayo (orforglipron) Oral Pill | FOUNDAYO (orforglipron) tablets, for oral use | Take FOUNDAYO orally once daily, with or without food. ( 2.1 ) Swallow tablets whole. Do not break, crush, or chew. ( 2.1 ) Do not take more than one tablet per day. | FDA label says "FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition." | DailyMed / USPL Reviewed: 2026-11-06 |
| Saxenda (liraglutide) Daily Pen | SAXENDA (liraglutide) injection, for subcutaneous use | Inject SAXENDA subcutaneously in the abdomen, thigh, or upper arm once daily at any time of day, without regard to the timing of meals. | FDA label says "SAXENDA is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. ( 1 ) • Adults with overweight in the presence of at least one weight-related comorbid condition." | DailyMed / USPL Reviewed: 2026-11-08 |
Estimated Monthly Out-of-Pocket Expenses by Insurance Type
Manufacturer savings card benefits differ depending on your employer plan formulary design.
| Medication | Commercial (Covered) | Commercial (Not Covered) | Direct Self-Pay Option | Medicare Part D |
|---|---|---|---|---|
Zepbound (tirzepatide) Weekly Injection | As low as $25 / month | ~$550 – $650 / month | LillyDirect vials: $399 – $549 / mo | Part D excludes weight loss |
Wegovy (semaglutide) Weekly Injection | As low as $25 / month | ~$650 – $850 / month | List price assistance (~$1,349) | Covered if established CVD |
Saxenda (liraglutide) Daily Injection | ~$25 – $150 / month | ~$700 – $900 / month | List price assistance (~$1,349) | Part D excludes weight loss |
Estimates reflect published 2026 manufacturer copay cards from Eli Lilly and Novo Nordisk. Medicare recipients are legally excluded from manufacturer coupons under the Anti-Kickback Statute.
Discussing These Differences With Your Doctor
Choosing between weekly injections (Wegovy/Zepbound) and daily oral tablets requires evaluating lifestyle adherence, baseline labs, and comorbidity coverage.
Route of Administration Preference
Discuss whether you prefer a single weekly subcutaneous autoinjector (Wegovy/Zepbound) or a daily tablet taken with plain water on an empty stomach.
Indication & Comorbidity Match
If you have documented cardiovascular disease (Wegovy indication) or moderate-to-severe sleep apnea (Zepbound indication), ask your provider to code these in your prior authorization.
Baseline Lab Orders (CMP, A1c)
Request routine bloodwork to check kidney filtration (eGFR) and glycemic status, preventing adverse events and satisfying PBM coverage criteria.
Data source: Official FDA-approved prescribing information on DailyMed (National Library of Medicine) and manufacturer Prescribing Information as of November 2026. This comparison does not substitute for clinical judgment. Brand names are trademarks of their respective owners.